Literature DB >> 10885831

Drug resistance in Plasmodium falciparum malaria.

D C Warhurst1.   

Abstract

Four classes of drugs are reviewed: blood schizontocides acting only on the hemoglobin-digesting blood stages, the antifolates which attack tetrahydrofolate synthesis in all the growing stages, antimitochondrials affecting synthesis and electron transport, and 8-aminoquinolines which interfere with redox processes. Drug efflux via a multidrug resistance membrane protein, and the production of a protein competing with the drug for the target hemin are thought to be responsible for resistance to blood schizontocides. Structural changes in target enzymes are responsible for easily-developed resistance to antifolates and antimitochondrials. The judicious use of drug combinations can help to avoid development of resistance and combat resistant infections, but new drugs are urgently needed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10885831     DOI: 10.1007/BF02561674

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  19 in total

1.  Preventing antimalarial drug resistance through combinations.

Authors:  N J White
Journal:  Drug Resist Updat       Date:  1998-03       Impact factor: 18.500

2.  Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand.

Authors:  S Looareesuwan; C Viravan; H K Webster; D E Kyle; D B Hutchinson; C J Canfield
Journal:  Am J Trop Med Hyg       Date:  1996-01       Impact factor: 2.345

3.  Access to hematin: the basis of chloroquine resistance.

Authors:  P G Bray; M Mungthin; R G Ridley; S A Ward
Journal:  Mol Pharmacol       Date:  1998-07       Impact factor: 4.436

4.  Characterization of the products of the heme detoxification pathway in malarial late trophozoites by X-ray diffraction.

Authors:  D S Bohle; R E Dinnebier; S K Madsen; P W Stephens
Journal:  J Biol Chem       Date:  1997-01-10       Impact factor: 5.157

5.  A randomized controlled trial of artemether/benflumetol, a new antimalarial and pyrimethamine/sulfadoxine in the treatment of uncomplicated falciparum malaria in African children.

Authors:  L von Seidlein; K Bojang; P Jones; S Jaffar; M Pinder; S Obaro; T Doherty; M Haywood; G Snounou; B Gemperli; I Gathmann; C Royce; K McAdam; B Greenwood
Journal:  Am J Trop Med Hyg       Date:  1998-05       Impact factor: 2.345

6.  The effect of combinations of qinghaosu (artemisinin) with standard antimalarial drugs in the suppressive treatment of malaria in mice.

Authors:  A N Chawira; D C Warhurst; B L Robinson; W Peters
Journal:  Trans R Soc Trop Med Hyg       Date:  1987       Impact factor: 2.184

7.  Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite.

Authors:  I K Srivastava; H Rottenberg; A B Vaidya
Journal:  J Biol Chem       Date:  1997-02-14       Impact factor: 5.157

Review 8.  Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy.

Authors:  S R Meshnick; T E Taylor; S Kamchonwongpaisan
Journal:  Microbiol Rev       Date:  1996-06

9.  Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria.

Authors:  R N Price; F Nosten; C Luxemburger; A Kham; A Brockman; T Chongsuphajaisiddhi; N J White
Journal:  Trans R Soc Trop Med Hyg       Date:  1995 Sep-Oct       Impact factor: 2.184

10.  Amplification of pfmdr 1 associated with mefloquine and halofantrine resistance in Plasmodium falciparum from Thailand.

Authors:  C M Wilson; S K Volkman; S Thaithong; R K Martin; D E Kyle; W K Milhous; D F Wirth
Journal:  Mol Biochem Parasitol       Date:  1993-01       Impact factor: 1.759

View more
  7 in total

1.  Drug susceptibility testing of anaerobic protozoa.

Authors:  J A Upcroft; P Upcroft
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  A plastid segregation defect in the protozoan parasite Toxoplasma gondii.

Authors:  C Y He; M K Shaw; C H Pletcher; B Striepen; L G Tilney; D S Roos
Journal:  EMBO J       Date:  2001-02-01       Impact factor: 11.598

3.  Alterations in Plasmodium falciparum genetic structure two years after increased malaria control efforts in western Kenya.

Authors:  Anne M Vardo-Zalik; Guofa Zhou; Daibin Zhong; Yaw A Afrane; Andrew K Githeko; Guiyun Yan
Journal:  Am J Trop Med Hyg       Date:  2012-11-19       Impact factor: 2.345

4.  Genome sequences reveal divergence times of malaria parasite lineages.

Authors:  Joana C Silva; Amy Egan; Robert Friedman; James B Munro; Jane M Carlton; Austin L Hughes
Journal:  Parasitology       Date:  2010-12-01       Impact factor: 3.234

5.  Molecular surveillance of drug-resistance associated mutations of Plasmodium falciparum in south-west Tanzania.

Authors:  Mirjam Schönfeld; Isabel Barreto Miranda; Mirjam Schunk; Ibrahim Maduhu; Leonard Maboko; Michael Hoelscher; Nicole Berens-Riha; Andrew Kitua; Thomas Löscher
Journal:  Malar J       Date:  2007-01-15       Impact factor: 2.979

6.  Molecular surveillance of drug resistance through imported isolates of Plasmodium falciparum in Europe.

Authors:  Tomas Jelinek; Gabriele Peyerl-Hoffmann; Nikolai Mühlberger; Ole Wichmann; Michael Wilhelm; Nadja Schmider; Martin P Grobusch; Frank von Sonnenburg; Joaquim Gascon; Hermann Laferl; Christoph Hatz; Michael Alifrangis; Gerd Burchard; Paul McWhinney; Marco Schulze; Herwig Kollaritsch; Saraiva da Cunha; Jiri Beran; Peter Kern; Ida Gjørup; Juan Cuadros
Journal:  Malar J       Date:  2002-10-11       Impact factor: 2.979

7.  Molecular evidence of increased resistance to anti-folate drugs in Plasmodium falciparum in North-East India: a signal for potential failure of artemisinin plus sulphadoxine-pyrimethamine combination therapy.

Authors:  Pradyumna Kishore Mohapatra; Devojit Kumar Sarma; Anil Prakash; Khukumoni Bora; Md Atique Ahmed; Bibhas Sarma; Basanta Kumar Goswami; Dibya Ranjan Bhattacharyya; Jagadish Mahanta
Journal:  PLoS One       Date:  2014-09-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.